Spero Therapeutics, Inc. - Common Stock (SPRO)
2.2150
-0.1350 (-5.74%)
NASDAQ · Last Trade: May 29th, 4:03 PM EDT

Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · May 29, 2025

Via Benzinga · May 28, 2025

Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · May 28, 2025

Via Benzinga · May 28, 2025

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.
Via Benzinga · May 28, 2025

The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.
Via Stocktwits · May 28, 2025

Via Benzinga · May 28, 2025

Via Benzinga · January 30, 2025

Via Benzinga · December 20, 2024

Via Benzinga · October 30, 2024

Via Benzinga · October 30, 2024

SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 5, 2024

Investors should know the risks of micro-cap stocks before looking into these three high-potential companies with low prices.
Via InvestorPlace · July 8, 2024

SPRO stock results show that Spero Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 15, 2024

Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metrics.
Via Benzinga · March 14, 2024

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Via Benzinga · March 14, 2024

It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning!
Via InvestorPlace · March 14, 2024